Must See: Keep Your Eyes on Akanda Corp. (NASDAQ: AKAN) Today

Following Our Recent Profiles That Made 37%, 188%, And 53% Approximate Moves, You Need To Immediately Turn Your Attention To  Akanda Corp. (NASDAQ: AKAN)! Akanda Corp. (NASDAQ: AKAN) Demands Your Immediate Attention Due To These Potential Catalysts: Ultra Low Float: Less Than 1.9M Shares, Potential For Significant Price Swings With Demand Changes! Under the Radar: Market Cap Under $3M (As Of 8/1/2024), Could Witness Rapid Valuation Changes Compared To Larger Companies! Robust Market Potential: Global (CB) Market Expected To Grow From  $13.4B To $148.9B By 2031! Expansion Into Canada: Acquired Canadian Farming Property In British Columbia, Plans For (CB) Facilities. German Market Entry: Evaluating Growth Plans And Acquisitions In Germany's CBPM Market, Projected To Reach Over $5.7B  By 2030. US Market Positioning: Preparing To Capitalize On (CB) Rescheduling To Schedule III In The US, Anticipating Favorable Market And Regulatory Changes! Do Not Miss Out on Akanda Corp. (NASDAQ: AKAN)! August 2, 2024 Dear Reader, Following our recent profiles that made 37%, 188%, and 53% approximate moves, you need to immediately turn your attention to Akanda Corp. (NASDAQ: AKAN). But you’ll need to be quick on this one because (AKAN) has less than 1.9M shares in its float, which means there’s the potential for significant price swings if there’s a shift in demand. Do not wait on this one. Akanda Corp. (NASDAQ: AKAN) is also considered a nano-cap.  In general, nano-cap companies have market capitalizations of less than $50M. Because nano-cap stocks are significantly smaller than mid cap or large cap companies, they have a higher potential to change valuation quickly. As of 8/1/2024, Akanda Corp. (NASDAQ: AKAN) has a market cap of less than $3M (approx.) according to FinViz. Recent price movement below the 5-Day MA of $1.3532 hints at a possible trend reversal. Its RSI values appear to be entering "oversold territory" (9-Day: 21.75%, 14-Day: 29.02%), suggesting that (AKAN) may be severely overlooked. Keep reading to see why Akanda Corp. (NASDAQ: AKAN) needs to be at the top of your watchlist right now. Akanda Corp. (NASDAQ: AKAN) is an international medical cann-a-bis (CB) and wellness platform company committed to enhancing lives through improved access to high-quality and affordable CB products.  The company’s extensive portfolio includes CanMart, a UK-based, fully licensed pharmaceutical importer and distributor that supplies pharmacies and clinics throughout the UK. In the UK, all pharmaceutical products containing C-B-D are referred to as CB-based products for medicinal use (CBPM). Akanda Corp. (NASDAQ: AKAN)’s comprehensive seed-to-patient supply chain is bolstered by its partnerships with notable entities such as Cellen Life Sciences' Leva Clinic, one of the first fully digital pain clinics in the UK.  Moreover, Akanda has acquired the rights to develop a Canadian farming property in British Columbia, which includes farming land, related operations, and licenses. The company plans to establish CB facilities at this site, further expanding its capabilities. Recent Developments In a strategic move, Akanda Corp. (NASDAQ: AKAN) has announced plans to commercialize and capitalize on Germany's recent le-gal-iza-tion of CBPM, which opens a pathway to a $3B market.  Germany, the third European Union country to LGLize CB for personal use after Malta and Luxembourg, enacted this law on April 1, 2024.  This LGLization permits recreational possession, allows individuals to grow up to three plants, and enables joining CB clubs to buy up to 25 grams per day. Akanda Corp. (NASDAQ: AKAN) anticipates significant growth potential in this expanded LGL market.  The company is actively evaluating potential acquisitions and strategic expansion in Germany, focusing on cultivation, production, and retail areas where its management and board have substantial experience.  Akanda Corp. (NASDAQ: AKAN) believes the expansion in both medical and recreational CBPM use will drive increased patient and consumer demand.  The company plans to closely monitor regulatory developments and the licensing process, as well as assess current licensed operating targets for potential acquisition. Akanda's interim CEO and Director, Katie Field, stated,  "We applaud Germany's increased access to valid medicine and products for patients and consumers. This legislation represents a critical step and illustrates a public policy model for other European Union countries. Akanda is evaluating the potential to participate at the leading edge of this market and aspires to provide German consumers with exceptional products." The German CBPM market, valued at approximately $1.17B in 2022, is projected to reach over $5.7B by 2030, exhibiting a CAGR of 22.05% during the forecast period 2023-2030. The LGLization and sale of CB are advancing rapidly not only in the U.S. but globally. Global CB sales are expected to increase from $13.4B to over $148B by 2031. Strategic Moves in the US Following Federal Policy Changes Akanda Corp. (NASDAQ: AKAN) is also positioning itself to be among the international first movers following the anticipated landmark change in US federal policy regarding CBPM.  It has been widely reported that the DEA plans to reclassify CB as a Schedule III substance as of April 30, 2024.  Akanda believes this rescheduling could reinvigorate capital markets and potentially lead to changes in NASDAQ and NYSE rules on listing plant-touching U.S. companies. In response to these potential changes, Akanda has strategic plans to become a leader in consolidating US-based operators.  The company is closely monitoring the loosening of federal regulations and plans to explore potential strategies within the US market.  Akanda's board and management have extensive expertise in multiple global markets, including the United States, and are prepared to capitalize on these developments. Key Market Insights Germany: Pioneering Shops for Scientific Purposes Germany is progressing with the second pillar of its CBPM LGLization law by setting up municipal five-year pilot programs for state-controlled CBPM to be sold in licensed shops. The Ministry of Agriculture is drafting regulations focused on the "permission and monitoring of the use of CBPM for scientific purposes." This innovative approach underscores Germany's commitment to creating a structured and regulated market. United Kingdom: Soaring Medical Sales The United Kingdom is experiencing unexpectedly high CBPM sales driven by unusually high per-patient consumption rates. A new report by Prohibition Partners reveals that by the end of 2024, approximately 62,960 patients in the UK will be using CBPM, generating sales of 240M eu-ros ($258.8M). This equates to an average annual consumption of 3,811 eur-os per patient, significantly higher than in Germany, where the average annual consumption per patient is 1,563 eur-os. Akanda Corp. (NASDAQ: AKAN) is strategically positioned to capitalize on significant market potential in both Europe and the United States. With a robust portfolio, strategic partnerships, and a proactive approach to regulatory changes, Akanda is poised to become a leader in the global CBPM industry.  The company's focus on high-quality, affordable products and its commitment to improving access for patients and consumers underline its potential for sustained growth and success in the rapidly evolving CBPM market. Here’s 7 reasons to immediately start your research on  Akanda Corp. (NASDAQ: AKAN). 1. Under the Radar: As a nano-cap company with a market cap of less than $3M (as of 8/1/2024), Akanda Corp. (NASDAQ: AKAN) has a higher potential for growth compared to larger companies. 2. Ultra Low Float: With less than 1.9M shares in its float, Akanda Corp. (NASDAQ: AKAN). can experience significant price movements with shifts in demand, making it a stock with potential volatility to monitor closely. 3. Robust Market Potential: The global CB market is expected to grow from $13.4B to over $148B by 2031, indicating a significant increase in demand and market size. 4. Strategic Global Partnerships: Akanda Corp. (NASDAQ: AKAN)’s portfolio includes CanMart, a UK-based pharmaceutical importer and distributor, and partnerships with entities like Cellen Life Sciences' Leva Clinic, enhancing its reach and credibility. 5. Expansion into Canada: The acquisition of a Canadian farming property in British Columbia, with plans to develop CB facilities, signifies Akanda Corp. (NASDAQ: AKAN)’s growth and diversification in North America. 6. German Market Entry: With Germany LGLizing CBPM, Akanda Corp. (NASDAQ: AKAN) is evaluating strategic moves and acquisitions in a market projected to reach over $5.7B by 2030, providing a substantial growth avenue. 7. US Market Positioning: Akanda Corp. (NASDAQ: AKAN) is preparing to capitalize on the anticipated rescheduling of CBPM as a Schedule III substance in the US, which could lead to favorable changes in market conditions and regulatory environment. With an ultra-low float of less than 1.9M shares, Akanda Corp. (NASDAQ: AKAN) has the potential for significant price swings as demand shifts. As a nano-cap company with a market cap of under $3M (as of 8/1/2024), Akanda can experience rapid valuation changes compared to larger companies. Akanda Corp. (NASDAQ: AKAN)’s strategic global partnerships, including CanMart in the UK and collaborations with entities like Cellen Life Sciences' Leva Clinic, bolster its reach and credibility. The company's expansion into Canada with a new farming property in British Columbia for developing CB facilities signifies its growth and diversification in North America. In Germany, where the CBPM market is projected to reach over $5.7B by 2030, Akanda is evaluating strategic growth potential and acquisitions. Additionally, the company is preparing to capitalize on the anticipated rescheduling of CBPM as a Schedule III substance in the US, which could lead to favorable regulatory changes. The global CBPM market is expected to grow from $13.4B to $148.9B by 2031, offering robust market potential. With experienced leadership and pioneering initiatives like setting up state-controlled CBPM shops in Germany for scientific purposes, Akanda is poised for significant growth. Don’t miss out—immediately start your research on Akanda Corp. (NASDAQ: AKAN). I mean it, Akanda Corp. (NASDAQ: AKAN) has a very small float so you’ll need to be ready early. Pull up (AKAN) and add it to the top of your watchlist right now. I’ll check back with you shortly. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 08/1/2024 and ending on 08/2/2024 to publicly disseminate information about (AKAN:US) via digital communications. Headline Media LLC has been paid five thousand USD to disseminate information about (AKAN:US) via digital communications. We own zero shares of (AKAN:US). Please find important disclosure information here: https://marketcrux.com/akan-disclosure-691/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice